Annovis Bio Inc (ANVS) Actualités

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 8-K - Current report

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace

LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization...

Form 8-K - Current report

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

October 3, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Pharmaceutical companies are demonstrating innovation by...

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

October 2, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Alzheimer’s disease (“AD”) has become a...

Form 8-K - Current report